Page last updated: 2024-10-31

modafinil and Neoplasms

modafinil has been researched along with Neoplasms in 31 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL)."9.41Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Deb, U; Mukhopadhyay, S, 2021)
"CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia."9.22Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016)
"The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients."9.22Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016)
"This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors."9.22Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. ( Barilla, H; Findley, JC; Garland, SN; Gehrman, P; Heckler, CE; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA, 2016)
"Modafinil may be useful in controlling cancer-related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue."9.14A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas ( Esparaz, BT; Heckler, C; Hemstad, A; Hopkins, JO; Janelsins, M; Jean-Pierre, P; Mohile, S; Morrow, GR; Peppone, L; Roscoe, JA, 2010)
"To review the efficacy and safety of modafinil in the treatment of cancer-related fatigue (CRF)."8.85Efficacy and safety of modafinil in the treatment of cancer-related fatigue. ( Bird, HM; Cooper, MR; Steinberg, M, 2009)
"the authors conducted an open-label investigation examining the effects of modafinil in reducing fatigue in patients with cancer, undergoing cancer treatment, and receiving opioid therapy."7.76[Modafinil for the treatment of cancer-related fatigue : an intervention study]. ( Junker, U; Kühn, KU; Nadstawek, J; Vater, S; Wartenberg, HC; Wirz, S, 2010)
"The aim of this study was to compare the efficacy and safety of modafinil and dexamethasone in the management of cancer-related fatigue and their effects on quality of life (QoL)."5.41Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study. ( Banerjee, S; Bhattacharya, B; Biswas, S; Deb, U; Mukhopadhyay, S, 2021)
"CBT-I with and without armodafinil resulted in a clinically and statistically significant reduction of subjective daytime fatigue in cancer survivors with chronic insomnia."5.22Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Hoefler, J; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Shayne, M, 2016)
"The aim of this study was to examine the effect of modafinil on depression via a secondary data analysis of a randomized clinical trial of modafinil for fatigue in cancer patients."5.22Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy. ( Conley, CC; Dakhil, S; Gross, H; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Palesh, OG; Peppone, LJ; Scalzo, AJ, 2016)
"This study involves the analysis of a secondary outcome of a trial examining whether cognitive behavior therapy for insomnia (CBT-I), a wake-promoting medication (armodafinil), or both results in greater improvement in prospectively assessed sleep continuity and daytime sleepiness than a placebo-alone group among a heterogeneous group of cancer survivors."5.22Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. ( Barilla, H; Findley, JC; Garland, SN; Gehrman, P; Heckler, CE; Kamen, C; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA, 2016)
"In this pilot study modafinil was well-tolerated and effective for fatigue in patients with cancer."5.14A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. ( Baum, L; Blackhall, L; Farace, E; Petroni, G; Shu, J, 2009)
"Modafinil may be useful in controlling cancer-related fatigue in patients who present with severe fatigue but is not useful in patients with mild or moderate fatigue."5.14A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas ( Esparaz, BT; Heckler, C; Hemstad, A; Hopkins, JO; Janelsins, M; Jean-Pierre, P; Mohile, S; Morrow, GR; Peppone, L; Roscoe, JA, 2010)
" We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis."4.91Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015)
"For the relief of chemotherapy symptoms in cancer patients, methylphenidate and modafinil were no more effective than placebo, although findings suggest that these psychostimulants may provide some benefit in patients who are suffering more severe asthenia or who are at advanced stages of the cancer."4.87The use of psychostimulants in cancer patients. ( Centeno, C; Portela, MA; Rubiales, AS, 2011)
" Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis."4.86Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010)
"To review the efficacy and safety of modafinil in the treatment of cancer-related fatigue (CRF)."4.85Efficacy and safety of modafinil in the treatment of cancer-related fatigue. ( Bird, HM; Cooper, MR; Steinberg, M, 2009)
"the authors conducted an open-label investigation examining the effects of modafinil in reducing fatigue in patients with cancer, undergoing cancer treatment, and receiving opioid therapy."3.76[Modafinil for the treatment of cancer-related fatigue : an intervention study]. ( Junker, U; Kühn, KU; Nadstawek, J; Vater, S; Wartenberg, HC; Wirz, S, 2010)
"Methylphenidate and modafinil were equivalent to one another."3.01Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis. ( Boldt, G; Bruera, E; Chiu, L; Chow, R; Lock, M; Prsic, E; Sanatani, M, 2023)
"We included participants with advanced cancer who were suffering from CRF."3.01Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer. ( Foster, K; Good, P; Hardy, JR; Haywood, A; Khan, S; Rickett, K; Sandford, A, 2023)
"In cancer survivors with insomnia, CBT-I resulted in clinically significant improvement in QOL via improvement in insomnia."2.84Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial. ( Garland, SN; Heckler, CE; Janelsins, MC; Kamen, CS; Morrow, GR; Mustian, KM; Peoples, AR; Peppone, LJ; Perlis, ML; Roscoe, JA; Ryan, JL; Savard, J, 2017)
"Insomnia was assessed by the Insomnia Severity Index and sleep quality by the Pittsburgh Sleep Quality Inventory."2.80Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. ( Daniels, NP; Garland, SN; Heckler, CE; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Savard, J; Shayne, M, 2015)
"MLN8054 dosing for up to 14 days of a 28-day cycle was feasible."2.76Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. ( Burris, H; Cohen, RB; Danaee, H; Dees, EC; Ecsedy, J; Eton, O; Fingert, H; Galvin, K; Infante, JR; Jones, S; Lee, Y; Liu, H; Manfredi, M; O'Neil, BH; Stringer, B; von Mehren, M, 2011)
"Fatigue is a common symptom experienced by people with cancer and other long-term, non-malignant conditions."2.61The holistic management of fatigue within palliative care. ( Dean, A, 2019)
"Pharmacotherapeutic approaches for cancer therapy-induced cognitive symptoms include CNS stimulants (eg, methylphenidate and modafinil), medications used in patients with memory impairment (eg, donepezil, memantine, and ginkgo biloba), and bone marrow supporting agents (eg, erythropoietin)."2.61Pharmacologic management of cognitive impairment induced by cancer therapy. ( Dietrich, J; Karschnia, P; Parsons, MW, 2019)
"Survivors of childhood cancer frequently experience cancer-related cognitive dysfunction, commonly months to years after treatment for pediatric brain tumors, acute lymphoblastic leukemia (ALL), or tumors involving the head and neck."2.50Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. ( Castellino, SM; Lange, BJ; Ullrich, NJ; Whelen, MJ, 2014)
"Methylphenidate has been studied most and is effective and well tolerated despite common side effects."2.44Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. ( Alici, Y; Breitbart, W, 2008)
"All patients with cancer should be evaluated for fatigue, and treatment options should be considered for those who are experiencing excessive levels of fatigue."2.43Management of cancer-related fatigue. ( Hickok, JT; Morrow, GR; Mustian, K; Roscoe, JA; Shelke, AR, 2005)

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (25.81)29.6817
2010's20 (64.52)24.3611
2020's3 (9.68)2.80

Authors

AuthorsStudies
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Chow, R1
Bruera, E1
Sanatani, M1
Chiu, L1
Prsic, E1
Boldt, G1
Lock, M1
Sandford, A1
Haywood, A1
Rickett, K1
Good, P1
Khan, S1
Foster, K1
Hardy, JR1
Dean, A1
Deb, U1
Mukhopadhyay, S1
Bhattacharya, B1
Banerjee, S1
Biswas, S1
Karschnia, P1
Parsons, MW1
Dietrich, J1
Miladi, N1
Dossa, R1
Dogba, MJ1
Cléophat-Jolicoeur, MIF1
Gagnon, B1
Barsevick, AM1
Irwin, MR1
Hinds, P1
Miller, A1
Berger, A1
Jacobsen, P1
Ancoli-Israel, S1
Reeve, BB1
Mustian, K2
O'Mara, A1
Lai, JS1
Fisch, M1
Cella, D1
Borghgraef, C1
Libert, Y1
Etienne, AM1
Delvaux, N1
Reynaert, C1
Razavi, D1
Castellino, SM1
Ullrich, NJ1
Whelen, MJ1
Lange, BJ1
Roscoe, JA6
Garland, SN4
Heckler, CE5
Perlis, ML4
Peoples, AR4
Shayne, M2
Savard, J2
Daniels, NP1
Morrow, GR7
Mücke, M1
Cuhls, H1
Peuckmann-Post, V1
Minton, O1
Stone, P1
Radbruch, L2
Qu, D1
Zhang, Z1
Yu, X1
Zhao, J1
Qiu, F1
Huang, J1
Kamen, C2
Hoefler, J1
Conley, CC1
Kamen, CS2
Janelsins, MC2
Peppone, LJ3
Scalzo, AJ1
Gross, H1
Dakhil, S1
Mustian, KM3
Palesh, OG2
Barilla, H1
Gehrman, P1
Findley, JC1
Ryan, JL1
Alfano, CM1
Heckler, C2
Kleckner, AS1
Kleckner, IR1
Leach, CR1
Mohr, D1
Piper, BF1
Scarpato, J1
Smith, T1
Sprod, LK1
Miller, SM1
Hampton, T1
McNeil, C1
Breitbart, W1
Alici, Y1
Cooper, MR1
Bird, HM1
Steinberg, M1
Blackhall, L1
Petroni, G1
Shu, J1
Baum, L1
Farace, E1
Lundorff, LE1
Jønsson, BH1
Sjøgren, P1
Jean-Pierre, P1
Mohile, S1
Janelsins, M1
Peppone, L1
Hemstad, A1
Esparaz, BT1
Hopkins, JO1
Dees, EC1
Infante, JR1
Cohen, RB1
O'Neil, BH1
Jones, S1
von Mehren, M1
Danaee, H1
Lee, Y1
Ecsedy, J1
Manfredi, M1
Galvin, K1
Stringer, B1
Liu, H1
Eton, O1
Fingert, H1
Burris, H1
Wirz, S1
Nadstawek, J1
Kühn, KU1
Vater, S1
Junker, U1
Wartenberg, HC1
Peuckmann, V1
Elsner, F1
Krumm, N1
Trottenberg, P1
Portela, MA1
Rubiales, AS1
Centeno, C1
Shelke, AR1
Hickok, JT1
Spathis, A1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924]42 participants (Anticipated)Interventional2020-08-01Recruiting
Feasibility Study of a Hypnosis Intervention and a Cognitive Behavioral Therapy Intervention to Reduce Fatigue in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer[NCT04999306]60 participants (Anticipated)Interventional2023-05-17Recruiting
Effect of Resistance Training Variable Manipulation (Intensity and Volume) on Body Composition, Fatigability and Functional Capacity in Postmenopausal Breast Cancer Survivors.[NCT03644329]80 participants (Anticipated)Interventional2018-05-13Recruiting
MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19[NCT04632719]200 participants (Anticipated)Interventional2020-11-08Recruiting
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy[NCT01091974]Phase 2138 participants (Actual)Interventional2008-02-29Completed
Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Adjuvant Chemotherapy[NCT06137833]92 participants (Anticipated)Interventional2023-11-27Not yet recruiting
Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy[NCT01440621]Phase 3217 participants (Actual)Interventional2010-08-31Completed
Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of The Effect Of Modafinil On Fatigue In Cancer Patients Receiving Chemotherapy[NCT00042848]Phase 3837 participants (Anticipated)Interventional2002-08-31Completed
A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067]Phase 1/Phase 29 participants (Actual)Interventional2013-08-14Completed
Randomized Controlled Trial of Exercise to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer[NCT02846389]24 participants (Actual)Interventional2016-06-21Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Insomnia Severity Index From Baseline to Post-intervention

The Insomnia Severity Index (ISI) is a commonly used, 7-item psychometrically validated measure used to rate insomnia with 0-7 = absence of insomnia, 8-14 = subthreshold insomnia symptoms, 15-21 = moderate insomnia, and 22-28 = severe insomnia. (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).

Interventionunits on a scale (Mean)
Arm 1 - (CBT-I) + Placebo-4.93
2 - CBT-I + Armodafinil-6.36
3- Placebo Only1.04
4 - Armodafinil Only-1.43

Fatigue Will be Assessed by the Total Score of the Revised Brief Fatigue Inventory (BFI) .

"The revised Brief Fatigue Inventory (BFI) is a 9-item, patient-report instrument with established reliability and validity. The BFI allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue. Three items ask patients to rate their fatigue now, and fatigue at its worst and usual for the last 24 hours. The 11-point scales are bounded by 0 = no fatigue and 10 = fatigue as bad as you can imagine. Using the same type of scales, the remaining questions ask patients to rate how their fatigue interferes with several functional domains, including general activity, walking, mood, work, and relations with others. These scales are bounded by 0 = does not interfere and 10 = interferes completely. A global fatigue score (ranging from 0-10) can be obtained by averaging all the items on the BFI." (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).

Interventionunits on a scale (Mean)
Arm 1 - (CBT-I) + Placebo2.041
2 - CBT-I + Armodafinil1.209
3- Placebo Only2.971
4 - Armodafinil Only3.167

Number of Participants With a PSA Value Equal to or Greater Than 25%

Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months

InterventionParticipants (Count of Participants)
Treatment (Alisertib, Abiraterone Acetate, Prednisone)3

Phase I: Frequency of Dose Limiting Toxicities of Alisertib, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1

Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days

InterventionParticipants (Count of Participants)
Treatment (Alisertib, Abiraterone Acetate, Prednisone)2

Reviews

16 reviews available for modafinil and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
    BMJ supportive & palliative care, 2023, Volume: 13, Issue:3

    Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Network M

2023
Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer.
    The Cochrane database of systematic reviews, 2023, 01-23, Volume: 1

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Dexamethasone; Fatigue; Humans; Modafinil; Neoplasms; Qu

2023
The holistic management of fatigue within palliative care.
    International journal of palliative nursing, 2019, Aug-02, Volume: 25, Issue:8

    Topics: Central Nervous System Stimulants; Chronic Disease; Cognitive Behavioral Therapy; Complementary Ther

2019
Pharmacologic management of cognitive impairment induced by cancer therapy.
    The Lancet. Oncology, 2019, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Central Nervous System Stimulants; Cholinesterase Inhibitors; Cognitive Dysfu

2019
Psychostimulants for cancer-related cognitive impairment in adult cancer survivors: a systematic review and meta-analysis.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019, Volume: 27, Issue:10

    Topics: Adult; Cancer Survivors; Central Nervous System Stimulants; Cognition; Cognitive Dysfunction; Humans

2019
[Treatment of cognitive impairments in oncology: a review of longitudinal controlled studies].
    Bulletin du cancer, 2014, Volume: 101, Issue:9

    Topics: Adult; Benzhydryl Compounds; Case-Control Studies; Central Nervous System Stimulants; Cognition; Cog

2014
Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:8

    Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Attention; Benzhydryl Compounds; Br

2014
Pharmacological treatments for fatigue associated with palliative care.
    The Cochrane database of systematic reviews, 2015, May-30, Issue:5

    Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea

2015
Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis.
    European journal of cancer care, 2016, Volume: 25, Issue:6

    Topics: Benzhydryl Compounds; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Psychotropic Drugs

2016
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen

2017
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen

2017
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen

2017
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
    JAMA oncology, 2017, Jul-01, Volume: 3, Issue:7

    Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphen

2017
Pharmacologic treatment options for cancer-related fatigue: current state of clinical research.
    Clinical journal of oncology nursing, 2008, Volume: 12, Issue:5 Suppl

    Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Cholinesterase Inhib

2008
Efficacy and safety of modafinil in the treatment of cancer-related fatigue.
    The Annals of pharmacotherapy, 2009, Volume: 43, Issue:4

    Topics: Animals; Benzhydryl Compounds; Fatigue; Humans; Modafinil; Neoplasms; Randomized Controlled Trials a

2009
Pharmacological treatments for fatigue associated with palliative care.
    The Cochrane database of systematic reviews, 2010, Nov-10, Issue:11

    Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney

2010
The use of psychostimulants in cancer patients.
    Current opinion in supportive and palliative care, 2011, Volume: 5, Issue:2

    Topics: Adult; Antineoplastic Agents; Asthenia; Benzhydryl Compounds; Central Nervous System Stimulants; Chi

2011
Management of cancer-related fatigue.
    Cancer investigation, 2005, Volume: 23, Issue:3

    Topics: Antidepressive Agents; Benzhydryl Compounds; Depression; Fatigue; Glucocorticoids; Humans; Modafinil

2005

Trials

10 trials available for modafinil and Neoplasms

ArticleYear
Efficacy and safety of modafinil versus dexamethasone in cancer-related fatigue: a prospective randomized controlled study.
    Future oncology (London, England), 2021, Volume: 17, Issue:14

    Topics: Administration, Oral; Adult; Aged; Dexamethasone; Double-Blind Method; Fatigue; Female; Follow-Up St

2021
Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-10, Volume: 33, Issue:2

    Topics: Benzhydryl Compounds; Breast Neoplasms; Cognitive Behavioral Therapy; Combined Modality Therapy; Fem

2015
Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:5

    Topics: Benzhydryl Compounds; Cognitive Behavioral Therapy; Combined Modality Therapy; Fatigue; Female; Foll

2016
Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy.
    Journal of clinical psychopharmacology, 2016, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Depression; Double-Blind Method; F

2016
Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors.
    Sleep medicine, 2016, Volume: 20

    Topics: Benzhydryl Compounds; Cognitive Behavioral Therapy; Disorders of Excessive Somnolence; Female; Human

2016
Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial.
    Journal of cancer survivorship : research and practice, 2017, Volume: 11, Issue:3

    Topics: Adult; Aged; Benzhydryl Compounds; Cognitive Behavioral Therapy; Female; Humans; Male; Middle Aged;

2017
A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue.
    Journal of palliative medicine, 2009, Volume: 12, Issue:5

    Topics: Activities of Daily Living; Affect; Benzhydryl Compounds; Central Nervous System Stimulants; Drug-Re

2009
Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial.
    Palliative medicine, 2009, Volume: 23, Issue:8

    Topics: Adult; Aged; Attention; Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders

2009
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
    Cancer, 2010, Jul-15, Volume: 116, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner

2010
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
    Cancer, 2010, Jul-15, Volume: 116, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner

2010
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
    Cancer, 2010, Jul-15, Volume: 116, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner

2010
A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research bas
    Cancer, 2010, Jul-15, Volume: 116, Issue:14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzhydryl Compounds; Central Ner

2010
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aurora Kinases; Benzaze

2011

Other Studies

5 other studies available for modafinil and Neoplasms

ArticleYear
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Recommendations for high-priority research on cancer-related fatigue in children and adults.
    Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19

    Topics: Adult; Anxiety; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clinical

2013
Cancer investigators make strides in improving patients' quality of life.
    JAMA, 2008, Jul-23, Volume: 300, Issue:4

    Topics: Acupuncture Therapy; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Modaf

2008
No rest for fatigue researchers.
    Journal of the National Cancer Institute, 2008, Aug-20, Volume: 100, Issue:16

    Topics: Activities of Daily Living; Anemia; Antineoplastic Agents; Benzhydryl Compounds; Central Nervous Sys

2008
[Modafinil for the treatment of cancer-related fatigue : an intervention study].
    Schmerz (Berlin, Germany), 2010, Volume: 24, Issue:6

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Central Nervous Sy

2010
Medicinal studies in palliative care: impact of the EU clinical trials directive.
    Palliative medicine, 2007, Volume: 21, Issue:1

    Topics: Benzhydryl Compounds; Biomedical Research; Central Nervous System Stimulants; Clinical Trials as Top

2007